Talk:Plasma membrane monoamine transporter

I am planning on editing this article. Many of the inhibitors and substrates late citations, which I will attempt to find and add. The article lacks an introduction and ligands sections, which I will add. I will also make some QoL changes to the existing text to make it flow more logically. I will also add in the information from user:ffangs after vetting it. I will propose my edits here, and apply them after allowing a few days for discussion. --Johnskad (talk) 23:52, 30 October 2023 (UTC)

I will separate the main body of the page into an intro with general information on PMAT, and then a body with more specific sections. I am planning on a General Structure and Function section and a Clinical Significance section. I am also looking to remove the Ligands section because I have yet to find any. It should be readded if such a thing is discovered. Johnskad (talk) 17:37, 7 November 2023 (UTC)

I have completed my draft of the article, and it is in my sandbox. I would appreciate any feedback on my proposed changes prior to uploading them here. In short, I have created a clinical significance section, reformatted the existing content, removed some outdated information, removed the ligands section, added new inhibitors and substrates, and updated many of the citations.There has been quite a lot of additions, so any feedback would be more than welcome - every source I used was a review article but one, in the depression section of clinical significance. I believe the included primary research article is quite good, and brings up some very good, overlooked points about the differential expression of PMAT between age groups, but would appreciate a second opinion on its inclusion. --Johnskad (talk) 19:29, 28 November 2023 (UTC)

As a note, the bulleted lists are becoming long in the ligands and substrates sections. In significantly more are identified and added here, these lists would likely benefit by being condensed into a table or paragraph. — Preceding unsigned comment added by Johnskad (talk • contribs) 03:06, 9 December 2023 (UTC)

To add

In cells stably expressing PMAT and SERT, the apparent affinity of recombinant PMAT for 5-HT is much lower than that of SERT (Km, 114 v.s. 0.5 μM) [12, 15]. However, PMAT also has a much larger transport capacity (Vmax), resulting in roughly comparable uptake efficiencies (Vmax/Km) to SERT in heterologous expression systems

The most potent inhibitors are fluvoxamine and sertraline, followed by paroxetine and fluoxetine, and then by citalopram. The concentrations of SSRIs required to produce an inhibitory effect on PMAT are much higher than the steady state free drug concentrations commonly encountered clinically (Table 3) [23, 24], suggesting that the activity of PMAT is not affected by the SSRIs at clinically used dosages.

PMAT, together with the OCTs, may play a significant role in 5-HT clearance in brain regions where expression of SERT is low or when SERT function is pharmacologically inhibited, such as chronic use of antidepressants.

In the brain, SERT mRNA is known to be highly localized to serotonergic neurons in median and dorsal raphe nuclei and the caudal linear nucleus. In contrast, our previous Northern blot showed that PMAT mRNA is abundantly expressed in the human brain in all regions.

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1828907

ffangs (talk) 05:43, 6 July 2009 (UTC)

Wiki Education assignment: BYU-Biophysics, CELL 568

This article was the subject of a Wiki Education Foundation-supported course assignment, between 5 September 2023 and 14 December 2023. Further details are available on the course page. Student editor(s): Johnskad (article contribs). Peer reviewers: OtherwiseDrummer, AzulRover.

— Assignment last updated by OtherwiseDrummer (talk) 16:36, 19 October 2023 (UTC)